Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge (SOHO 2026) - Sep 1, 2026 - Abstract #CLL-620; Location: LEVEL 3, HALL B3; "Treatment was complicated only by transient grade 4 neutropenia, recovering within 3–5 days with filgrastim...Ruxolitinib was started with initial count normalization...The patient received 1 cycle of obinutuzumab plus DHAP... This case highlights marrow-dominant aggressive progression of high-risk CLL/SLL after reactive myelofibrosis, creating a clinically relevant diagnostic dilemma between blastoid CLL/SLL progression and Richter transformation. It underscores the need for integrated morphologic, immunophenotypic, molecular, and clinical assessment, especially where limited access to targeted therapy influences disease trajectory and treatment selection. CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL: chronic lymphocytic leukemia; COVID-19: coronavirus disease 2019; DHAP: dexamethasone, cytarabine, and cisplatin; IGHV: immunoglobulin heavy chain variable region; JAK2: Janus kinase 2; SLL: small lymphocytic lymphoma; TP53: tumor protein..."
Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelofibrosis • Non-Hodgkin's Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • IGH • JAK2 • TP53
|
|
Adela Perolla MD PhD 1,2; Elsuarta Çalliku MD 2; Valentina Semanaj PhD 3; Teuta Dedej-Kurti MD PhD 3; Alma Rucaj MD PhD 3; Dorina Roko PhD 2; Anila Babameto MD PhD 1,2; Niki Struga MBBS 4; Arben Ivanaj MD PhD 1,2
|